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Abstract
Introduction: Long-term outcome is postulated to be different in isolated
methylmalonic aciduria caused by mutations in the MMAA gene (cblA type)
compared with methylmalonyl-CoA mutase deficiency (mut), but case defini-
tion was previously difficult.
Method: Cross-sectional analysis of data from the European Registry and Net-
work for Intoxication type Metabolic Diseases (Chafea no. December 1, 2010).
Results: Data from 28 cblA and 95 mut patients in most cases confirmed by
mutation analysis (including 4 new mutations for cblA and 19 new mutations
for mut). Metabolic crisis is the predominant symptom leading to diagnosis in
both groups. Biochemical disturbances during the first crisis were similar in
both groups, as well as the age at diagnosis. Z scores of body height and body
weight were similar in both groups at birth, but were significantly lower in the
mut group at the time of last visit. Glomerular filtration rate was significantly
higher in cblA; and as a consequence, chronic renal failure and related compli-
cations were significantly less frequent and renal function could be preserved
even in older patients. Neurological complications were predominantly found
in the mut subgroup. Methylmalonic acidemia (MMA) levels in urine and
plasma were significantly lower in cblA. 27/28 cblA patients were reported to
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be responsive to cobalamin, only 86% of cblA patients were treated with i.m.
hydroxocobalamin. In total, 73% of cblA and 98% of mut patients followed a
calculated diet with amino acid supplements in 27% (cblA) and 69% (mut).
During the study interval, six patients from the mut group died, while all cblA
patients survived.
Conclusion: Although similar at first, cblA patients respond to hydro-
xocobalamin treatment, subsequently show significantly lower levels of MMA
and a milder course than mut patients.
KEYWORD S
anthropometrics, chronic renal failure, dietary treatment, methylmalonic acidemia, movement
disorder, vitamin B12/hydroxocobalamin
1 | INTRODUCTION
Isolated methylmalonic acidemias (MMA) comprise a
group of diseases characterized by elevated concentra-
tions of methylmalonic acid in blood, urine, and other
body fluids. These disorders of propionate catabolism
are inherited in an autosomal recessive manner and
represent defects of L-methylmalonyl-CoA mutase
(MMUT, EC 5.4.99.2), the synthesis of its cofactor 50-
deoxyadenosylcobalamin, in rare cases deficiency of
the methylmalonyl-CoA epimerase (MCEE, EC
5.1.99.1) or of the succinate-CoA ligase (SUCLG1, EC
6.2.1.4; SUCLA2, EC 6.2.1.5). This study deals with
two distinct forms of MMA: the complete deficiency
of L-methylmalonyl-CoA mutase (mut, OMIM 251100)
and the deficiency of its accessory protein met-
hylmalonic acid type A protein (MMAA) (cblA, OMIM
251100). Already the first case series on natural his-
tory of MMA postulated major differences in outcome
between these two disease groups.1 Exact classifica-
tion based on propionate incorporation studies in cul-
tured skin fibroblasts remained difficult, making case
definition for clinical studies less clear.2,3 The genetic
basis of mut was unraveled in 1990,4 but it was only in
2002, that the gene responsible for cblA was localized
to chromosome 4q31.21.5 This gene, called MMAA,
encodes a G-protein belonging to the G3E family of P-
loop GTPases, which is responsible for proper incor-
poration of adenosylcobalamin into MUT.6,7
In this study, the clinical picture of MMA due to
cblA is compared to that of the deficiency of
methylmalonyl-CoA mutase activity (mut), focusing on
biochemical findings, molecular genetic data, disease
onset and major endpoints of clinical outcome: sur-
vival, growth, renal disease and neurological complica-
tions and reports details on their medical and dietary
treatment.
SYNOPSIS
CblA patients treated with hydroxocobalamin
show significantly lower levels of methylmalonic
acid and have a milder clinical course than mut
patients.
2 | PATIENTS AND METHODS
2.1 | European Registry and Network for
Intoxication type Metabolic Diseases
The European Registry and Network for Intoxication type
Metabolic Diseases (E-IMD, European Agency for Health
and Consumers No. 2010 12 01) received funding from
the European Union (EU) in the framework of the health
program 2008 to 2013. A detailed description of the regis-
try (https://www.eimd-registry.org) has been published
previously.8-10
The study was approved by the ethic committee of the
coordinating center (University Hospital Heidelberg,
Application No. S-525/2010) and consecutively by those
of all contributing metabolic centers. Written assent and
parental consent was obtained for all study patients
before enrolment and baseline visit in countries where
this was needed by law. Patients with unconfirmed suspi-
cion of an organic acid disorder, and with unrelated seri-
ous comorbidities and patients who died before January
2011, 01 (starting date of E-IMD) were excluded. For this
particular analysis data have been pulled from the data-
base in August 2016. For classification of cblA and mut
patients' diagnostic details (mutation analysis and
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enzyme studies) were reviewed by experts with long-
standing experience in the field and only patients with at
least two pathogenic variants or diagnostic enzyme stud-
ies have been included.
2.2 | Study population
One hundred twenty-three patients (56 female, 67 male)
with a confirmed diagnosis of isolated methylmalonic
aciduria from 17 countries and 26 centers were included
in this study. Details on age and sex of patients are shown
in Table 1 and both were equally distributed among both
subgroups. Study patients and their origins were hetero-
geneous. Most of them came from European countries,
that is, 27 patients were from France, 16 from Germany,
10 from Spain, 8 patients each from Great Britain and
Italy, 7 patients from Croatia, 6 patients each from the
Russian Federation and Denmark, 5 from the Czech
Republic, 4 from Serbia, 3 patients each from Austria and
the Netherlands, 2 patients each from Belgium and Swit-
zerland. Single patients came from Portugal and Roma-
nia. Other patients came from non-European countries,
that is, 9 patients came from Taiwan, 3 from the United
States and single patients each from Japan and the island
of Reunion.
Patients were classified as cblA or mut by enzyme
studies in cultured fibroblasts, as formerly described,2,11
through mutation analysis, or both. Four patients have
been classified as mut, leaning on the genetic testing of
an affected family member (eg, sibling). mut0 and mut−
are categories defined by enzyme studies, but enzyme
studies were not available for all patients. In order to
compare extreme phenotypes, patients with complete
deficiency of methylmalonyl-CoA mutase (enzyme stud-
ies or mutation analysis) have been preferentially chosen.
Body weight (BW), body length, and head circumfer-
ence at birth were compared by using z values
corresponding to gestational age as proposed by the
Royal College of Pediatrics and Child Health Growth
Chart Expert Group12 and for the other visits reference
values according to Cole et al13 were used, which are suit-
able until the age of 22 years. Glomerular filtration rate
(GFR) has been estimated by using the Schwartz for-
mula14 up to the age of 18, afterward modification of diet
in renal disease (MDRD) has been applied. Chronic renal
failure (CRF) was defined according to the European def-
inition as GFR < 60 mL/min/1.73 m2.
2.3 | Statistical analysis
All statistical computation was done with R, a language
for statistical computing and graphics (https://www.r-
project.org). A numeric response variable between two
groups was compared with a t test with Welch correction.
A multiple linear regression was used to analyze the
impact of the predictor variables age and cblA or mut on
the response variable GFR. Count data from contingency
tables were analyzed with a log-linear model. P values
reported were two-sided. P ≤ .05 was considered statisti-
cally significant.
3 | RESULTS
3.1 | Classification of patients and
variant analysis
Of the 123 patients, 28 were classified as cblA and 95 as
mut. Tables 2 and 3 show the details of diagnosis. In the
cblA group pathogenic variants c.433C>T (p.Arg145*)
and c.592_595delACTG (p.Thr198Serfs*6) were most fre-
quently found. In the mut group the pathogenic variant
c.655A>T (p.Asn219Tyr) was the most frequent. In this
study we identified four new pathogenic variants which
lead to the cblA phenotype: one nonsense variant
c.1098G>A (p.Trp366*) and one missense variant
c. 589A>G (p.Met197Val) and two deletions
c.662_664delCAA (p.Thr221del), c.593_596delCTGA (p.
Thr198Serfs*6). In the mut-group we identified 19 novel
pathogenic variants (Table 4). Cobalamin responsiveness,
as defined by the physician in charge, was reported in
27 of the 28 cblA patients and unexpectedly, also in a sin-
gle patient with mut. In one cblA patient cobalamin
responsiveness was not reported. Methylmalonic acid in
urine and plasma at the time of last visit were signifi-
cantly lower in cblA patients (Figure 1; urine: t
[55.6] = −6.6, P < .001, t test; plasma: t[36.9] = −4.6,
P < .001, t test).
3.2 | Medical and dietary treatment
Hydroxocobalamin supplementation was provided to
15 cblA patients, while 6 patients were treated by
TABLE 1 Study population: distribution among cblA and mut:
age distribution between groups was not significantly different (t
[33.9] = 1.63, P = .11, t test)
n Sex female: male Mean age (years)
cblA 28 11:17 11.9
mut 95 45:50 8.7
Total 123 56:67 9.4
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TABLE 2 Details on diagnosis of cblA patients: propionate fixation (pmol/16 h/mg protein) and mutase activity measurements (pmol/min/mg protein) were performed in fibroblasts and
expressed as percent of control activity (n = 28)
Nr.














+OH-Cbl −OH-Cbl +Ado-Cbl −Ado-CblMutation 2 (paternal)
Mutation 2
(paternal) Father
1 c.592_595delACTG p.Thr198Serfs*6 Germany Plessl et al15 56 19 182 27
c.592_595delACTG p.Thr198Serfs*6 Germany
2 c.586C>T p.Arg196* Germany Plessl et al15 38 10 48 30
c.586C>T p.Arg196* Turkey
3 c.586C>T p.Arg196* Germany Dempsey-Nunez et al16 and Plessl et al15 44 10 152 68
c.1196_1197delGGinsTT p.Gly399Val Austria
4 c.387C>A p.Tyr129* Portugal Lerner-Ellis et al17 - - - -
c.387C>A p.Tyr129* Portugal
5 c.387C>A p.Tyr129* Portugal Lerner-Ellis et al17 - - - -
c.387C>A p.Tyr129* Portugal
6 c.433C>Ta p.Arg145* Germany Lerner-Ellis et al17 and Dempsey-Nunez
et al16
- - - -
c.551dupCa p.Cys184Trpfs*3 Germany












9 N/A N/A Netherlands 9 4 50 10
N/A N/A Netherlands
10 c.586C>T p.Arg196* Croatia Plessl et al15 40 9 16 2
c.592_595delACTG p.Thr198Serfs*6 Croatia
11 c.592_595delACTG p.Thr198Serfs*6 Croatia Plessl et al15 45 13 - -
c.592_595delACTG p.Thr198Serfs*6 Croatia
12 c.283C>Ta p.Gln95* Denmark Plessl et al15 - - - -




























+OH-Cbl −OH-Cbl +Ado-Cbl −Ado-CblMutation 2 (paternal)
Mutation 2
(paternal) Father
13 N/A N/A N/A Diagnosis due to family history - - - -
N/A N/A N/A
14 c.433C>T p.Arg145* Denmark Lerner-Ellis et al17 - - - -
c.433C>T p.Arg145* Denmark
15 c.433C>T p.Arg145* Pakistan Lerner-Ellis et al17 - - - -
c.433C>T p.Arg145* Pakistan
16 c.433C>T p.Arg145* Pakistan Lerner-Ellis et al17 - - - -
c.433C>T p.Arg145* Pakistan
17 c.662_664delCAA p.Thr221del Tunisia Novel pathologic variant 40 - 5 -
c.662_664delCAA p.Thr221del Tunisia
18 N/A N/A Italy 74 19 29 27
N/A N/A Italy
19 c.593_596delCTGA p.Thr198Serfs*6 Serbia Novel pathologic variant – This variant
leads to the same protein change as the
c.592_595delACTG (Plessl et al15)
- - - -
c.593_596delCTGA p.Thr198Serfs*6 Serbia
20 c.592_595delACTG p.Thr198Serfs*6 Slovakia Plessl et al15 - - - -
c.592_595delACTG p.Thr198Serfs*6 Slovakia
21 c.592_595delACTG p.Thr198Serfs*6 Slovakia Plessl et al15 - - - -
c.592_595delACTG p.Thr198Serfs*6 Slovakia
22 N/A N/A Belgium 44 38 100 20
N/A N/A Belgium
23 c.742C>T p.Gln248* Cambodia Plessl et al15 - - - -
c.742C>T p.Gln248* Cambodia
24 c.551dupG p.Cys184Trpfs*3 Czech
Republic
Plessl et al15 - - - -
c.551dupG p.Cys184Trpfs*3 Czech
Republic














cyanocobalamin only and 1 patient was treated by
both. For the other six cblA patients, no information
was provided regarding cobalamin supplementation,
although five of them are reported to be responsive.
Hydroxocobalamin was mostly given to cblA patients
by intramuscular injection (n = 12/14 [86%]), only in
single cases orally [n = 1/14 [7%]) or by subcutaneous
injection (n = 1/14 [7%]). In the mut group, 12 patients
were supplemented with hydroxocobalamin, 5 by
intramuscular injection and 7 received oral
hydroxocobalamin.
L-Carnitine supplementation was provided to both
groups: the cblA group was given a median/mean dosage
of 52.4/52.7 mg/kg BW/d (min. 11.5-max. 102.6), while
the mut group was provided a significant higher median/
mean dosage of 70.9/77.7 mg/kg BW/d (min. 19.3-max.
200.0) (t[43.7] = −4.1, P < .001, t test).
Information on dietary treatment was available for
26 cblA and 89 mut patients: all mut patients were on
some kind of specialized diet, whereas 19.2% (n = 5/26)
of cblA patients were not. 73.1% (n = 19/26) of cblA com-
pared to 97.8% (n = 87/89) of mut patients followed a cal-
culated diet, while 7.7% of cblA (n = 2/26) and 2.2% mut
(n = 2/89) only avoided food with high protein content.
Amino acid supplements were added to the dietary treat-
ment for 27% of cblA (n = 7/26) and 69% of mut patients
(n = 61/88).
3.3 | Initial presentation
Overall, 90% of mut (n = 81/90) patients and 78% of
cblA (n = 21/27) patients have been classified as
“symptomatic” by their physicians. Metabolic crisis
was the leading manifestation in 76% (n = 16/21) of
cblA and 96% (n = 77/80) of mut patients (P < .05, log-
linear model). An initial crisis in the neonatal period
was reported in 43% (n = 9/21) of cblA and 60%
(n = 48/80) of mut patients. 33% (n = 7/21) of cblA and
36% (n = 29/80) of mut patients had their initial crisis
beyond the neonatal age, whereas 24% (n = 5/21) of
cblA and 4% (n = 3/80) of mut patients had no meta-
bolic crisis at all. Details on the diagnostic process and
laboratory values during first crisis are summarized in
Table 5: Laboratory values were similar in both
groups. The median age at first symptoms was higher
in the cblA group (24.5 days) than in the mut group
(5 days), although the difference was not statistically
significant (W = 915, P = .13, Wilcoxon rank sum test).
Neither the time of diagnosis (t[34.8] = 1.2, P = .237,
t test) nor the diagnostic delay (defined as the time
between the age at first symptoms and the age at diag-
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TABLE 3 Details on diagnosis of mut patients: propionate fixation (pmol/min/mg protein) and mutase activity measurements (pmol/min/mg protein) were performed in fibroblasts and
expressed as percent of control activity (n = 93)
Nr.













+OH-Cbl −OH-Cbl +Ado-Cbl −Ado-CblMutation 2 (paternal)
Mutation 2
(paternal) Father
1 c.607G>Aa p.Gly203Arg Germany Forny et al19 2 3 2 15
c.1105C>Ta p.Arg369Cys Germany
2 c.862T>Ca p.Ser288Pro Germany Forny et al19 - - - -
c.1157A>Ga p.His386Arg Germany
3 c.1280G>Aa p.Gly427Asp N/A Worgan et al20 and Forny et al19 - - - -
c.1677-1G>Aa Splice mutation Germany
4 c.1106G>A p.Arg369His Russian
Fed.
Forny et al19 - - - -
c.1106G>A p.Arg369His Russian
Fed.
5 c.1489G>T p.Glu497* Russian
Fed.
Forny et al19 7 6 13 100
c.2193-2196dupTGCC p.Val733Cysfs*6 Russian
Fed.
6 c.607G>A p.Gly203Arg Germany Forny et al19 4 4 6 14
c.607G>A p.Gly203Arg Germany
7 c.850G>Aa p.Gly284Arg Russian
Fed.
Forny et al19 - - - -
c.1073T>Ca p.Leu358Pro Russian
Fed.
8 c.982C>T p.Leu328Phe Turkey Forny et al19 - - - -
c.982C>T p.Leu328Phe Turkey
9 c.643G>Aa p.Gly215Ser Russian
Fed.
Forny et al19 - - - -
c.2179C>Ta p.Arg727* Azerbaijan





























+OH-Cbl −OH-Cbl +Ado-Cbl −Ado-CblMutation 2 (paternal)
Mutation 2
(paternal) Father
11 c.2T>Ca p.Met1? Russian
Fed.
Forny et al19 - - - -
c.850G>Aa p.Gly284Arg Russian
Fed.
12 c.655A>T p.Asn219Tyr Russian
Fed.




13 c.1677-1G>A Splice mutation China Liu et al22
Novel pathologic variant
15 15 4 22
c.224delA p.Lys75Argfs*14 China
14 c.655A>Ta p.Asn219Tyr Morocco Forny et al19
Novel pathologic variant
- - - -
c.904G>Ca p.Ala302Pro Morocco
15 c.198delGa p.Ile67Serfs*3 France Worgan et al20
Novel pathologic variant
- - - -
c.1332+1delGa Splice mutation France
16 c.1106G>A p.Arg369His N/A Forny et al19 13 14 0 0
c.1106G>A p.Arg369His N/A
17 c.689C>G p.Thr230Arg N/A Forny et al19
Novel pathologic variant
5 5 6 74
c.1991C>T p.Ala664Val N/A
18 c.927G>Aa p.Trp309* Great
Britain
Forny et al19 - - - -
c.983T>Ca p.Leu328Pro Spain
19 c.1844C>T p.Pro615Leu Italy Forny et al19 - - - -
c.1844C>T p.Pro615Leu Italy
20 N/A N/A Italy Family history - - - -
N/A N/A Italy
21 c.630delA p.Glu211Argfs*12 Italy Forny et al19 - - - -
c.330T>G p.Tyr110* Italy

































p.Ala732Trpfs*6 Italy Forny et al19 - - - -
c.655A>T p.Asn219Tyr Italy
24 c.655A>Ta p.Asn219Tyr Italy Forny et al19 - - - -
c.1106G>Aa p.Arg369His Italy
25 c.330T>G p.Tyr110* Italy Forny et al19 - - - -
c.330T>G p.Tyr110* Italy
26 N/A N/A Netherlands 11 8 - -
N/A N/A Netherlands
27 c.654A>C p.Gln218His Netherlands Forny et al19 - - - -
c.654A>C p.Gln218His Netherlands
28 c.129G>A p.Trp43* Croatia Forny et al19 10 9 1 27
c.129G>A p.Trp43* Croatia
29 c.129G>A p.Trp43* Croatia Forny et al19 - - - -
c.129G>A p.Trp43* Croatia
30 N/A N/A Croatia 13 14 3 7
N/A N/A Croatia
31 c.1658del p.Val553Glyfs*17 Croatia Forny et al19 - - - -
c.1658del p.Val553Glyfs*17 Croatia
32 N/A N/A Croatia 12 11 2 7
N/A N/A Croatia
33 c.-39-1G>A Splice mutation Iraq Forny et al19 5 5 11 62
c.-39-1G>A Splice mutation Iraq
34 c.1957-2A>G Splice mutation Denmark Worgan et al20 14 13 0 -





























+OH-Cbl −OH-Cbl +Ado-Cbl −Ado-CblMutation 2 (paternal)
Mutation 2
(paternal) Father
35 c.1531C>G p.Arg511Gly Pakistan Novel pathogenic variant—the nucleotide
change “c.1531C>T” with the protein
change “p.Arg511*” has been published
previously by Forny et al19
16 10 1 16
c.1531C>G p.Arg511Gly Pakistan
36 c.1420C>T p.Arg474* France Forny et al19 - - - -
c.1531C>T p.Arg511* France
37 c.731A>T p.Asp244Val France Novel pathologic variant 5 - 0 -
c.731A>T p.Asp244Val France
38 c.607G>A p.Gly203Arg France Forny et al19 - - - -
c.322C>T p.Arg108Cys France
39 c.481G>A p.Gly161Arg France Mendez et al23 and Forny et al19 - - - -
c.671_678dupAATTTATG p.Val227Asnfs*16 France
40 N/A N/A Turkey 12 12 5 0
N/A N/A Turkey
41 c.1897_1900dupGTTA p.Ile634Serfs*8 France Novel pathologic variant - - - -
c.1897_1900dupGTTA p.Ile634Serfs*8 France
42 c.1531C>Ta p.Arg511* France Worgan et al20 and Forny et al19 - - - -
c.1924G>Ca p.Gly642Arg France
43 c.572C>A p.Ala191Glu Haiti Worgan et al20 and Forny et al19 - - - -
c.1867G>A p.Gly623Arg Haiti
44 c.572C>A p.Ala191Glu Haiti Worgan et al20 and Forny et al19 - - - -
c.1867G>A p.Gly623Arg Haiti
45 c.655A>T p.Asn219Tyr France Forny et al19
Novel pathologic variant
- - - -
c.1911delA p.Phe638Leufs*10 France
46 c.655A>Ta p.Asn219Tyr France Worgan et al20 and Forny et al19 - - - -
c.1149G>Ta p.Gln383His France





























+OH-Cbl −OH-Cbl +Ado-Cbl −Ado-CblMutation 2 (paternal)
Mutation 2
(paternal) Father
48 c.769insA p.Asn257Lysfs*6 Algeria Novel pathologic variant - - - -
c.769insA p.Asn257Lysfs*6 Algeria
49 c.1025C>Aa p.Ser342* France Acquaviva et al24 and Worgan et al20 - - - -
c.1332+1delGa Splice mutation France
50 N/A N/A Reunion 4 4 1 -
N/A N/A Reunion
51 c.655A>T p.Asn219Tyr France Forny et al19
Novel pathologic variant
- - - -
c.1911delA p.Phe638Leufs*10 France
52 c.322C>Ta p.Arg108Cys N/A Forny et al19 - - - -
c.1531C>Ta p.Arg511* N/A
53 c.2053_2055dup p.Leu685dup Switzerland Forny et al19 9 9 0 0
c.91C>T p.Arg31* Switzerland
54 c.91C>Ta p.Arg31* Switzerland Forny et al19 - - - -
c.2080C>Ta p.Arg694Trp Switzerland
55 c.1036_1038delCTT p.Leu346del France Worgan et al20 - - - -
c.1036_1038delCTT p.Leu346del France




- - - -
c.1646T>C p.Leu549Pro Rep. of
Serbia




- - - -
c.1690G>T p.Glu564* Rep. of
Serbia




- - - -
c.1922T>C p.Leu641Pro Montenegro

































60 c.655A>T p.Asn219Tyr Czech Rep. Forny et al19 - - - -
c.655A>T p.Asn219Tyr Czech Rep.
61 c.655A>Ta p.Asn219Tyr Czech Rep. Forny et al19 - - - -
N/A N/A Czech Rep.
62 c.655A>T p.Asn219Tyr Czech Rep. Forny et al19 - - - 5
c.2179C>T p.Arg727* Czech Rep.
63 c.655A>T p.Asn219Tyr Czech Rep. Forny et al19
Novel pathologic variant
- - - -
c.1881T>Aa p.His627Gln Czech Rep.
64 c.544dup p.Met182Asnfs*29 N/A Forny et al19 - - - -
c.544dup p.Met182Asnfs*29 N/A
65 c.544dup p.Met182Asnfs*29 N/A Forny et al19 3 4 - -
c.544dup p.Met182Asnfs*29 N/A
66 c.1280G>A p.Gly427Asp Taiwan Worgan et al20 and Yi et al25 - - - -
c.1495G>A p.Ala499Thr Taiwan
67 c.454C>Ta p.Arg152* Taiwan Worgan et al20 - - - 0
c.1280G>Aa p.Gly427Asp Taiwan
68 c.1280G>A p.Gly427Asp Taiwan Worgan et al20 - - - -
c.1280G>A p.Gly427Asp Taiwan
69 c.1655C>T p.Ala552Val Taiwan Forny et al19 - - - 1
c.982C>T p.Leu328Phe Taiwan
70 c.323G>Aa p.Arg108His Taiwan Worgan et al20 and Forny et al19 - - - 1
c.1280G>Aa p.Gly427Asp Taiwan
71 c.1280G>Aa p.Gly427Asp Taiwan Worgan et al20 and Liu et al22 - - - -
c.1677-1G>Aa Splice mutation Taiwan
72 c.1147C>G p.Gln383Glu China Forny et al19
Novel pathologic variant





























+OH-Cbl −OH-Cbl +Ado-Cbl −Ado-CblMutation 2 (paternal)
Mutation 2
(paternal) Father
73 c.1885A>G p.Arg629Gly Morocco Perez et al26 - - - -
c.1885A>G p.Arg629Gly Morocco
74 N/A p.Gln103Arg Spain Forny et al19
Novel pathologic variant (?)
- - - -
c.572C>A p.Ala191Glu Spain
75 N/A N/A Spain - - 0 0
N/A N/A Spain
76 c.1421G>C p.Arg474Pro Spain Forny et al19
Novel pathologic variant
- - - -
c.655A>T p.Asn219Tyr Spain
77 c.655A>T p.Asn219Tyr Romania Forny et al19 - - - -
c.655A>T p.Asn219Tyr Romania
78 c.731A>Ta p.Asp244Val Germany Novel pathologic variant - - - -
N/A N/A Germany
79 c.982C>T p.Leu328Phe Turkey Forny et al19 3 3 - -
c.982C>T p.Leu328Phe Germany
80 c.1560+1A>T Splice mutation France Acquaviva et al24 and Worgan et al20 2 2 2 -
c.785G>A p.Ser262Asn France
81 c.323G>Aa p.Arg108His France Forny et al19 - 16 1 -
c.655A>Ta p.Asn219Tyr France
82 c.983T>C p.Leu328Pro France Forny et al19
Novel pathologic variant
- 20 - -
c.104delA p.Gln35Argfs*17 France
83 c.643G>A p.Gly215Ser France Forny et al19 - - - -
c.643G>A p.Gly215Ser France
84 c.655A>T p.Asn219Tyr France Forny et al19 - - - -
c.1022dupA p.Asn341Lysfs*20 France
85 N/A N/A Spain Family history - - - -
N/A N/A Spain

































87 c.257C>Ta p.Pro86Leu El Salvador Worgan et al20 - - - -
c.671_678dup8a p.Val227Asnfs* El Salvador
88 c.850G>Ta p.Gly284* Kenya Forny et al19
Novel pathologic variant
- - - -
c.1043G>Ta p.Arg348Ile United
States
89 c.682C>T p.Arg228* United
States
Forny et al19 3 3 - -
c.1106G>A p.Arg369His United
States
90 c.1885A>G p.Arg629Gly Morocco Perez et al26 - - - 0
c.1885A>G p.Arg629Gly Morocco
91 c.977G>A p.Arg326Lys Spain Worgan et al20 and Forny et al19 - - 0 -
c.454C>T p.Arg152* Spain
92 c.977G>A p.Arg326Lys Spain Worgan et al20 and Forny et al19 - - - -
c.454C>T p.Arg152* Spain
93 c.655A>T p.Asn219Tyr Spain Perez et al26 and Forny et al19 - 2 - 0
c.458T>A p.Val153Asp Spain
Note: If a mutation has been mentioned twice, it is a homozygous mutation. In order to keep the number of references low, the most recent publication has been mentioned in the comments.
The bold entries represent the novel pathogenic variants in the cblA and mut-groups found in this study.
Abbreviations: Ado-Cbl, adenosylcobalamin; OH-Cbl, hydroxocobalamin.













patients in comparison to the cblA group (t
[17.6] = 1.0, P = .349, t test).
3.4 | Anthropometric development
Gestational ages were similar in both groups: cblA (mean
39.6 weeks ± 1.23 [min. 37-max. 42 weeks of gestation]) and
mut (mean 39.3 weeks ± 1.72 [min. 32-max. 42 weeks of ges-
tation]). Different problems during pregnancy have been
reported in mothers of 4/23 cblA (17%) and 14/83 mut (17%)
patients, such as gestational diabetes or arterial hypertonia,
not showing any specific pattern. BW, body length, and head
circumference were not significantly different between the
two subgroups at birth (BW: t[28.9] = 1.1, P = .297, t test;
body length: t[22.4] = 0.86, P = .400, t test; head circumfer-
ence: t[29.8] = 0.95, P = .349, t test). When compared longitu-
dinally, head circumference showed no significant difference
between the groups at the time of last visit, although a trend
with 6% decrease in the mut group was noticeable (t
[34.1] = 1.9, P = .062, t test). On the other hand, BW and
body length measurements at last visit were significantly
lower in mut patients (BW: t[38.2] = 2.0, P < .05, t test; body
length: t[33.5] = 3.1, P < .05, t test) (Figure 2).
TABLE 4 List of novel pathogenic variants both in the cblA and mut-group found in this study
cblA
c.589A>G c.593_596delCTGA c.662_664delCAA c.1098G>A







































The bold entries represent the novel pathogenic variants in the cblA and mut-groups found in this study.
FIGURE 1 Methylmalonic acid levels in urine and plasma of the cblA and mut patients at the time of last visit. Values in the cblA
subgroup are significantly lower than in the mut subgroup both in urine as well as in plasma. Patients with CRF (GFR < 60 mL/
min/1.73 m2) were excluded. Urine: cblA (n = 16); mut (n = 52). Plasma: cblA (n = 14); mut (n = 37) (urine: t[55.6] = −6.6, P < .001, t test;
plasma: t[36.9] = −4.6, P < .001, t test). CRF, chronic renal failure; GFR, glomerular filtration rate
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3.5 | Renal manifestations
Information on kidney function was available for 23 cblA
and for 69 mut patients. GFR, as estimated by the Schwartz
formula or the MDRD equation, was significantly higher in
cblA patients. Consequently CRF and related complications
were significantly less frequent and renal function pre-
served even in older cblA patients; whereas GFR dimin-
ished significantly in mut patients over the course of the
disease (Figure 3). The frequency of CRF was 46%
(n = 32/69) in the mut group vs 9% (n = 2/23) in the cblA
group. In six cblA patients (median age 16.5 years [min.
5-max. 34 years]) cystatin C measurements showed normal
levels and cystatin C-based estimations of GFR were nor-
mal. Arterial hypertension as a common complication of
CRF was present in 1 cblA (n = 1/22 [5%]) and 11 mut
patients (n = 11/73 [15%]). End-stage renal failure requiring
hemodialysis or peritoneal dialysis was reported in 2 cblA
and 3 mut patients. 5 mut patients (n = 5/90 [6%]) under-
went kidney transplantation, whereas none of the cblA
patients were transplanted during the study period.
3.6 | Gastrointestinal manifestations
Acute pancreatitis, a known complication in organic
acidurias, was reported in 4 mut patients. Feeding difficulties
leading to nasogastric tube (NG) feeding or percutaneous
endoscopic gastrostomy (PEG) was more frequent in mut
patients (PEG: n = 23/88 [26%], NG: n = 12/88 [14%]) than
in cblA patients (PEG: n = 1/27 [4%], NG: n = 3/27 [11%])
with an odd ratio of 5.5; however, the difference in frequency
was statistically not significant (P = .28, Fisher's exact test).
3.7 | Cardiac manifestations
Investigations of the heart were available for only a few
patients: 1/5 cblA patients had an abnormal electrocar-
diogram (ECG) and 1/8 had an abnormal echocardio-
gram (ECG: n = 1/5 [20%], echocardiogram n = 1/8
[13%]). 4/23 mut patients had an abnormal ECG and
4/32 had an abnormal echocardiogram (ECG: n = 4/23
[17%], echocardiogram n = 4/32 [13%]), but further
details have not been reported.
3.8 | Neurological manifestations
None of the 27 cblA patients were reported to have sei-
zures, whereas 10 patients from the mut group were diag-
nosed with epilepsy (n = 10/90 [11%]; χ2[1] = 3.3;
P = .07, log-linear model). One patient in the cblA group
(n = 1/27 [4%]) showed movement disorders, compared
to 29 patients from the mut group (n = 29/89 [30%];
χ
2[1] = 9.0; P < .05, log-linear model). Optic atrophy was
present in a single mut patient.
Information about schooling was available in 18 cblA
and 49 mut patients. A larger percentage of patients from
the cblA group attended regular school than the mut
group (cblA: n = 14/18 [78%]; mut: n = 24/49 [49%]) with
an odds ratio of 3.6. The statistical differences were sig-
nificant at a 6% level (P = .051, Fisher's exact test).
3.9 | Survival
During the study interval six mut patients (n = 6/95
[6%]) died, while all cblA patients survived. Cause of
TABLE 5 Initial metabolic crises in cblA and mut patients:



















Mode of diagnosis (%)
• Metabolic work-up of
symptomatic patients
(selective screening)








































Note: Laboratory features of initial crisis are similar in both groups
(NH3: t[58.9] = −1.58, P = .019, t test; pH: t[11.9] = −0.14,
P = .889, t test; BE: t[12.1] = −0.37, P = .715; lactate t[10.9] = 0.78,
P = .452), as well as the time of first symptoms (t[26.7] = 0.5,
P = .600, t test) and the diagnostic delay (defined as the time
between the age at first symptoms and the age at diagnosis in days)
(t[17.6] = 1.0, P = .349, t test).
The bold entries represent the novel pathogenic variants in the cblA
and mut-groups found in this study.
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death was reported by the physician in charge (not
proven by autopsy) to be brain edema in three patients
(at the ages of 5, 6, and 20 years), one patient died at the
age of 20 days, following a severe infectious disease. The
remaining two patients died at the ages of 2 and 13 years.
Causes of death of these patients were not reported.
4 | DISCUSSION
This study presents clinical data of 28 cblA and 95 mut
patients with a definite case definition. In the cblA
group two truncating mutations, c.433C>T (p.Arg145*)
and c.592_595delACTG (p.Thr198Serfs*6), were most
frequently found, which is in accordance with other
studies.15,17 This is the largest clinical cohort of cblA
patients published so far, and in earlier studies cblA
patients have been difficult to differentiate from other
subgroups.3 We compared the clinical picture of cblA-
type MMA to that of deficiency of methylmalonyl-CoA
mutase activity (mut). Presentation was by metabolic
crisis in both groups and similar biochemical distur-
bances were found, although cblA patients tended to
present later. This makes this group also a good candi-
date for newborn screening. For cobalamin non-
responsive patients it has already been shown that
patients diagnosed by newborn screening have less fre-
quent motor disorders and delay of motor milestones
than patients diagnosed after developing clinical
symptoms.27
Anthropometrics at birth in both groups show lower
z scores compared to a reference population,
corresponding to earlier reports of a lower birth weight in
MMA patients (without further differentiation of sub-
groups).8-10 While weight, length, and head circumfer-
ence do not differ at birth between both groups, BW and
length become significantly lower in mut patients over
time, whereas head circumference is not significantly dif-
ferent between both groups at the time of last visit. There
are several possible reasons for this: 40% of mut patients
have significant feeding difficulties leading to PEG or
NG-tube feeding contrasting to only 15% in the cblA
group. A recent study by Molema et al28 showed that in
the E-IMD MMA patient cohort, plasma L-valine and L-
isoleucine levels were very low, mainly in patients receiv-
ing amino acid mix (AAM), despite median daily natural
protein intake being at the recommended daily allow-
ance. Patient subgroups were not further subdivided in
that study. In our cohort, 98% of mut patients follow a
calculated diet with amino acid supplements in 69%.
Therefore, they may also be at risk of having amino acid
imbalances and these patients need careful monitoring
FIGURE 2 Anthropometrics in cblA and mut patients at birth and at last visit. SD scores of body weight, body length, and head
circumference at birth and at last visit are shown as boxplots: All three anthropometric parameters are similar in both subgroups at birth
(body weight: t[28.9] = 1.1, P = .270, t test; body length: t[22.4] = 0.86, P = .400, t test; head circumference: t[29.8] = 0.95, P = .349, t test).
Body weight and body length are significantly lower in mut patients at last visit compared to cblA patients, whereas the head circumference
is not significantly lower at the time of last visit (body weight: t[38.2] = 2.0, P < 0.05, t test; body length: t[33.5] = 3.1, P < .05, t test; head
circumference t[34.1] = 1.9, P = .062, t test)
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and regular adjustments of dietary treatment according
to the monitoring protocol proposed in the current guide-
line.11 This is also of importance for the fraction of cblA
patients who follow a calculated diet and take AAM.
In our study, neurological complications such as
movement disorders were significantly more frequent
in the mut group, whereas no differences could be seen
regarding seizures. Patients with organic acid disor-
ders from the E-IMD cohort show increased frequen-
cies of intellectual disability and behavioral/emotional
problems.29 Unfortunately, there is not sufficient data
on formal intelligence quotient testing available in the
cblA/mut subgroups, but if one uses regular schooling
as a surrogate parameter the cblA patients have a bet-
ter outcome. Interestingly, all four adult cblA patients
in the study live independently. Aspects such as cogni-
tive outcome, social development, and professional
integration need to be studied in more detail in future
studies.
Chronic renal failure is the most important somatic
long-term complication in MMA3,11 and has already been
demonstrated in the E-IMD cohort.8-10 In this study, only
8% of cblA showed CRF whereas 46% of mut patients did,
which is in accordance with percentages in earlier
studies.
Interestingly, we were able to demonstrate that in
most cblA patients GFR is preserved, even in older
patients. The estimates of GFR by Schwarz' formula and
MDRD are based on creatinine, which has to be inter-
preted with caution because, in pediatric patients with a
low muscle mass, creatinine tends to underestimate the
extent of renal damage. Therefore, cystatin C may be
more reliable in this population.30 Unfortunately, this
parameter was not available in all participating centers.
Nevertheless in six cblA patients cystatin C values were
available, which were all normal.
The pathogenesis of chronic renal failure in MMA
remains to be elucidated in detail and may be part of a
multisystem involvement of altered energy metabolism
via different synergistically acting mitochondrial
toxins.31-33 Concentrations of methylmalonic acid in
urine and especially in plasma are important predictors
of CRF.3,31,34 In this study methylmalonic acid in urine
and plasma were significantly lower in cblA patients,
corresponding to the higher GFR and lower incidence
of CRF.
FIGURE 3 A multiple regression with response GFR and predictors mutation (mut/cblA) and age of individuals in years shows a
significant interaction: While the GFR remains stable along life time for cblA patients (n = 23), GFR significantly decreases by nearly
3 points per year for mut patients (n = 69) (slope[mut] = −2.92, t[88] = −2.5, P < .02). GFR, glomerular filtration rate
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The response to cobalamin treatment has been
suggested to be an important predictor of outcome35 and
therefore should be assessed in every MMA patient.11 All
cblA patients except one (who remained unclear) were
reported to be cobalamin responsive. One major short-
coming of this study, and also an important problem in
patient management, is to specifically test for cobalamin
responsiveness. Although a test protocol has been
proposed,2 it may be difficult to apply in some patients
because it requires metabolic stability, which cannot be
reached when hydroxocobalamin is withdrawn. Unfortu-
nately, the in vitro response to hydroxocobalamin in
enzyme testing assays cannot be extrapolated to the
in vivo situation.36 Nevertheless, early and adequate
hydroxocobalamin supplementation in responsive
patients is crucial to postpone and even prevent chronic
renal failure.37 Further studies are needed to investigate
the optimal dosage and target range of methylmalonic
acid and if alternative use of cyanocobalamin orally is
also suitable.
In conclusion cblA patients are responsive to
hydroxocobalamin treatment and show significantly
lower levels of MMA and a milder course than mut
patients.
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